cy, starting and stopping, straining, poor flow rate,
incomplete emptying of the bladder and getting up at night to
urinate (nocturia). The patient scores the frequency of each
problem on a scale of 0 (not at all) to 5 (almost always). The
resulting AUA Symptom Score ranges from 0 points (no symptoms) to
35 points (severe). A score of 8 points or more indicates moderate
to severe symptoms warranting consideration of treatment
options.
BPH is a common disorder of older men, afflicting approximately
half of men over age 50 and close to 90% of men by age 80. The
disorder causes difficulties with urination associated with aging,
such as urination at night, urge to void frequently, hesitancy,
weak stream, and other problems.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. The
conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed
from time to time in Nymox's filings with the United States
Securities and Exchange Commission and other regulatory
authorities.
Contact
Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com
'"/>Page: 1 2 Related medicine technology :1.
Clinical Data From Nymox BPH Drug To Be Presented at American
Urological Association Meeting2.
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings3.
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207
for BPH4.
Nymox Announces Positive Results from Newly Completed Long-term
Study of NX-1207 for Benign Prostatic Hyperplasia5.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial6.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis7.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis8.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial9.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine10.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis11.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone